Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
| Autor: | Tannir, N.M., Albigès, L., McDermott, D.F., Burotto, M., Choueiri, T.K., Hammers, H.J., Barthélémy, P., Plimack, E.R., Porta, C., George, S., Donskov, F., Atkins, M.B., Gurney, H., Kollmannsberger, C.K., Grimm, M.-O., Barrios, C., Tomita, Y., Castellano, D., Grünwald, V., Rini, B.I., Jiang, R., Desilva, H., Fedorov, V., Lee, C.-W., Motzer, R.J. |
|---|---|
| Zdroj: | In Annals of Oncology November 2024 35(11):1026-1038 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|